FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2719-2722 December 27, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by van Deutekom, J. C. PubMed Citation

"Personalized molecular medicine." As with other catchy terms for big ideas, such as "reversing global warming" and "renewable energy," the concept of personalized molecular medicine is certainly important, but the path to achieving it is far from clear. When such phrases are considered, definitions are important. Does personalized molecular medicine mean the tailoring of drugs for the individual patient, an approach that evokes images of Bones on Star Trek making instantaneous diagnoses with his Tricorder followed by loud pneumatic injections of customized drugs? Such a concept would place the realization of this technology in the same time frame as the . . . [Full Text of this Article]

Source Information

From the Departments of Pediatrics, Neuroscience, and Biochemistry and Molecular Biology, George Washington University School of Medicine, and the Research Center for Genetic Medicine, Children's National Medical Center — both in Washington, DC.

This article has been cited by other articles:

• Jearawiriyapaisarn, N., Moulton, H. M., Sazani, P., Kole, R., Willis, M. S. (2009). Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 0: cvp335v2-cvp335 [Abstract] [Full Text]  
• Daniels, S. R. (2009). The Use of BMI in the Clinical Setting. Pediatrics 124: S35-S41 [Abstract] [Full Text]  
• Yokota, T., Takeda, S., Lu, Q.-L., Partridge, T. A., Nakamura, A., Hoffman, E. P. (2009). A Renaissance for Antisense Oligonucleotide Drugs in Neurology: Exon Skipping Breaks New Ground. Arch Neurol 66: 32-38 [Abstract] [Full Text]